| Category | Details |
| Definition | Psychiatric disorders are mental health conditions that affect mood, thinking, and behavior. Schizophrenia and bipolar disorder are chronic conditions characterized by psychosis, mood swings, and functional impairments. |
| Global Epidemiology | – Schizophrenia affects ~24 million people worldwide (~0.32% of the global population). |
| – Bipolar disorder affects ~40 million people globally (~0.5–1% prevalence). |
| – High comorbidity with substance use disorders and anxiety disorders. |
| Prevalence in Key Regions | – United States: Approximately 3.7 million people with schizophrenia and around 7 million with bipolar disorder. |
| – European Union: Estimated at around 4 million schizophrenia cases and approximately 7.5 million bipolar disorder cases annually |
| – India: ~6 million schizophrenia cases; ~12 million bipolar disorder cases. |
| – China: Estimated ~8 million schizophrenia cases; ~15 million with bipolar disorder. |
| – Caribbean: Estimated ~200,000 cases of schizophrenia and bipolar disorder combined. |
| Medicinal Cannabis Approvals | – United States (FDA): No specific approvals for psychiatric disorders; ongoing research into CBD for anxiety and psychosis. |
| – Canada: CBD products authorized for anxiety and PTSD; off-label use for psychosis in schizophrenia. |
| – European Union (EMA): Limited cannabinoid approvals; CBD and THC studied for psychosis and bipolar disorder management. |
| – Australia (TGA): Approved CBD for anxiety management in 2021; used off-label for psychosis. |
| – Israel: Cannabis-based treatments authorized for anxiety and psychosis in 2013. |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Reduces psychosis severity; shown to improve anxiety and cognitive symptoms in schizophrenia and bipolar disorder. |
| – THC (Tetrahydrocannabinol): Psychoactive; potential to worsen psychosis; limited to very low doses for anxiety or PTSD. |
| – CBG (Cannabigerol): Early evidence suggests anxiolytic properties; under investigation for its role in managing mood disorders. |
| – THCV (Tetrahydrocannabivarin): Promising evidence for reducing psychosis severity without psychoactive effects. |
| Mechanism of Action | – CBD: Modulates serotonin (5-HT1A) receptors and reduces dopamine dysregulation in schizophrenia. |
| – THCV: Partial agonist at CB1 receptors; reduces psychosis symptoms and may counteract THC’s psychoactive effects. |
| Key Clinical Studies | – McGuire et al., 2018: CBD significantly reduced psychosis severity in schizophrenia patients. |
| – Bhattacharyya et al., 2020: CBD improved cognitive function and reduced symptoms in early psychosis. |
| – Englund et al., 2017: THCV reduced psychosis severity and improved anxiety symptoms in schizophrenia patients. |
| – Black et al., 2022: Cannabinoids improved sleep quality and reduced anxiety in bipolar disorder patients. |
| Dosage Guidelines | – CBD (Oral): 300–800 mg/day for psychosis and anxiety; titrate based on response. |
| – THCV (Experimental): Early trials use 10–20 mg/day; limited clinical data available. |
| – CBG (Experimental): 5–15 mg/day in preclinical trials for anxiety and mood stabilization. |
| Administration Methods | – Oral Capsules: Consistent dosing for chronic management; preferred method for psychiatric conditions. |
| – Sublingual Oils: Rapid absorption; useful for acute anxiety episodes. |
| – Inhalation: Not recommended due to variability in dosing and risk of psychoactive effects. |
| Adverse Effects | – CBD: Mild effects: diarrhea, fatigue, appetite changes; rare: elevated liver enzymes. |
| – THC: Increased risk of psychosis, anxiety, and dependence; use with caution in psychiatric disorders. |
| – THCV: Minimal side effects in early trials; potential for mild gastrointestinal discomfort. |
| Research Gaps | – Long-term safety and efficacy studies of cannabinoids like THCV and CBG in psychiatric disorders are needed. |
| – Studies needed to evaluate cannabinoids as adjuncts to antipsychotic medications. |
| Opportunities in the Caribbean | – High Prevalence: Estimated ~200,000 cases of schizophrenia and bipolar disorder combined, with gaps in access to psychiatric care. |
| – Cannabis Clinics: Developing cannabinoid-focused mental health clinics could address local needs and attract international patients. |
| – Research Hub: Leveraging regional expertise to conduct cannabinoid-based psychiatric research. |
